Julia Shumkov
Medical · Sun City, AZNPI 1528579950
Payments from drug & device makers
Across 334 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$750
- Novartis$546
- AstraZeneca$521
- UCB, Inc.$428
- Lilly USA, LLC$317
- Teva Pharmaceuticals USA, Inc.$312
- plus $3K from 46 others
What the payments were for
- Food & beverage$5,80999%
- Education$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,896 in reported general payments places this provider in the 85th percentile of 748 medical providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $97,634 |
| MounjaroTirzepatide | 47 | $78,701 |
| TrulicityDulaglutide | 45 | $71,836 |
| FarxigaDapagliflozin Propanediol | 49 | $69,650 |
| JardianceEmpagliflozin | 28 | $44,200 |
| EliquisApixaban | 22 | $32,944 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $21,118 |
| XareltoRivaroxaban | 13 | $17,168 |
| JanuviaSitagliptin Phosphate | 12 | $14,028 |
| Lagevrio (Eua)Molnupiravir | 13 | $8,563 |
| Gabapentin | 138 | $3,222 |
| Pregabalin | 44 | $2,054 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 35 | $2,030 |
| Duloxetine Hcl | 62 | $1,906 |
| Rosuvastatin Calcium | 127 | $1,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $317 | $150,53692 claims |
| Novo NordiskOzempic | $114 | $97,63471 claims |
| AstraZenecaFarxiga | $521 | $69,65049 claims |
| Boehringer IngelheimJardiance | $53 | $44,20028 claims |
| PfizerEliquis | $89 | $32,94422 claims |
| MerckJanuvia, Lagevrio (Eua) | $44 | $22,59025 claims |
| GSKTrelegy Ellipta | $128 | $21,11817 claims |
| Johnson & JohnsonXarelto | $43 | $17,16813 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $118 | $1,764151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 748 medical providers in Arizona.
Other medical in Sun City
- Robert CasquejoScottsdale$474K
- Andrew HicksPeoria$460K
- Darren WestScottsdale$206K
- Linda MoorsTucson$122K
- Jamie WystrachScottsdale$79K
- Scott YoungPhoenix$69K
- Scott LightfootPhoenix$61K
- Jennifer KiserPhoenix$53K
- Lakeisha ColterPhoenix$48K
- Amy IngersollPhoenix$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.